Use of AP-1 activators to treat glaucoma and ocular hypertension
Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed.
1 . A topical composition for treating glaucoma or ocular hypertension comprising an AP-1 Activator and a pharmaceutically acceptable vehicle.
2 . A composition according to claim 1 , wherein the AP-1 Activator is selected from the group consisting of: β-naphthoflavone, tert-butylhydroquinone, and sulpiride.
3 . A composition according to claim 2 , wherein the AP-1 Activator is tert-butylhydroquinone.
4 . A composition according to claim 1 , wherein the composition comprises:
about 0.01 to 2.0% w/v t-HBQ;
about 0.28% w/v sodium phosphate;
about 0.8% w/v sodium chloride;
about 0.01% w/v benzalkonium chloride about 0.5% w/v HPMC;
about 0.1% w/v edetate disodium; and water
5 . A method for treating glaucoma or ocular hypertension which comprises administering to a mammal a composition comprising an AP-1 Activator and a pharmaceutically acceptable vehicle.
6 . A method according to claim 5 , wherein the AP-1 Activator is selected from the group consisting of: β-naphthoflavone, tert-butylhydroquinone, and sulpiride.
7 . A method according to claim 6 , wherein the AP-1 Activator is tert-butylhydroquinone.
8 . A method according to claim 5 , wherein the composition comprises:
about 0.01 to 2.0% w/v t-HBQ;
about 0.28% w/v sodium phosphate;
about 0.8% w/v sodium chloride;
about 0.01% w/v benzalkonium chloride
about 0.5% w/v HPMC;
about 0.1% w/v edetate disodium; and water.